Holen Sie sich die Stockscreener-App
0.5571
89.75%
0.2635
Mangoceuticals Inc Aktie (MGRX) Neueste Nachrichten
Mangoceuticals Inc (MGRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Mangoceuticals Inc (MGRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mangoceuticals Inc (MGRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mangoceuticals Inc (MGRX) Cash Flow - TradingKey
Mangoceuticals Inc (MGRX) Income Statement - TradingKey
MGRX|Mangoceuticals Inc|Price:0.542|Chg%:-0.001 - TradingKey
MGRX|Mangoceuticals Inc|Price:0.521|Chg%:-0.037 - TradingKey
Mangoceuticals Inc (MGRX) Institutional Confidence - TradingKey
Mangoceuticals, Inc. Revenue Breakdown – NASDAQ:MGRX - TradingView
Mangoceuticals Inc (MGRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Mangoceuticals stock doubles after Texas lawsuit - MSN
MGRX Q3 2025 Earnings: Net Loss Widens as Pre-Revenue Biotech Focuses on Clinical PipelineEarnings Outlook Update - DonanımHaber
Price to sales forward of Mangoceuticals, Inc. – BOATS:MGRX - TradingView
Mangoceuticals (MGRX) Slips 2.46% as Stock Approaches Key Support at $0.34Time Weighted Price - dars.gov.et
MGRX Q3 2025 Earnings: Wider Loss Reported as Stock Gains Despite Opaque Financial DisclosureBasic EPS Analysis - dars.gov.et
Price to earnings forward of Mangoceuticals, Inc. – NASDAQ:MGRX - TradingView
ETFs Investing in Mangoceuticals, Inc. Stocks - TradingView
Mangoceuticals (MGRX) Surges 10% as Stock Bounces from Key Support LevelGEX Level - dars.gov.et
Mangoceuticals, Inc. Subscription Agreement: Accredited Investor Requirements & SEC Compliance Explained - Minichart
Mangoceuticals Raises Capital via Private Equity Placement - TipRanks
Mangoceuticals (MGRX) completes $272,000 private placement of common shares - Stock Titan
Mangoceuticals Inc. (MGRX) Faces Continued Pressure, Testing Key Support Near $0.34Strangle Setup - dars.gov.et
Mangoceuticals, Inc. announced that it has received $0.272 million in funding - marketscreener.com
Mangoceuticals Inc (MGRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mangoceuticals (MGRX) Rallies 3.46% as Buyers Defend $0.34 SupportChannel Projection - dars.gov.et
Mangoceuticals Inc (MGRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Trending Stocks Today | Mangoceuticals Soars 41.16% Post-Market - Moomoo
MGRX Q3 2025 Earnings: Widening Losses and No Revenue as Mangoceuticals Navigates Pre‑Commercial Phase - dars.gov.et
MGRX Q3 2025 Earnings: EPS Loss of $0.69; Stock Declines 4.61% Amid Limited DataFinancial Data - DonanımHaber
Mangoceuticals Inc (MGRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Mangoceuticals Inc (MGRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
MGRX Q3 2025 Earnings: Loss Per Share Pressures Stock as Revenue Remains UndisclosedPeak Earnings Alert - dars.gov.et
MGRX Q3 2025 Earnings: EPS Loss of -$0.69 Highlights Ongoing Operational ChallengesPerformance Review - newsline.com
MGRX Price Today: Mangoceuticals, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Mangoceuticals (MGRX) Proxy Filing Summary - Quartr
MGRX Q3 2025 Earnings: Loss Reported, No Revenue Disclosed as Stock DeclinesLong-Term Guidance - dars.gov.et
MGRX Technical Analysis & Stock Price Forecast - Intellectia AI
Number of shareholders of Mangoceuticals, Inc. – NASDAQ:MGRX - TradingView
MGRX Q3 2025 Earnings: EPS of -$0.69 Reflects Ongoing Investment; Shares Dip 2.56%Subscription Growth Report - The Legal Advocate
MGRX Q3 2025 Earnings: Narrowing Losses as Strategic Pivot Gains MomentumSaaS Earnings Trends - DonanımHaber
MGRXMangoceuticals Inc Stock Price and Quote - Finviz
MGRX Q3 2025 Earnings: EPS Surprises with -$0.69 Loss as Revenue Remains UndisclosedROA Comparison - The Legal Advocate
Mangoceuticals Inc. (MGRX) Holds Near $0.44 After Marginal Uptick — Support and Resistance TightenVolume Profile - Newser
MANGOCEUTICALS, INC. 1Q 2026: Revenue $67.9K, EPS $(0.22) — 10-Q Summary - TradingView
Mangoceuticals (NASDAQ: MGRX) Q1 2026 shows small sales, heavy loss and thin cash - Stock Titan
MGRX: Net loss narrowed but liquidity and Nasdaq compliance risks persist, requiring urgent funding - TradingView
Mangoceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Mangoceuticals Delays Quarterly Filing After Audit Review - TipRanks
[NT 10-Q] MANGOCEUTICALS, INC. SEC Filing - Stock Titan
MGRX Stock Price, Quote & Chart | MANGOCEUTICALS INC (NASDAQ:MGRX) - ChartMill
MGRX (Mangoceuticals) Q3 loss widens, but stock rallies 7% on positive outlook.Rating Upgrade - Newser
0.84%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):